Biostar Pharmaceuticals Stock Net Income
| BSPM Stock | USD 0.0001 0.00 0.00% |
Biostar Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Biostar Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Biostar Pharmaceuticals' valuation are provided below:Biostar Pharmaceuticals does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Biostar |
Biostar Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Biostar Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Biostar Pharmaceuticals.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Biostar Pharmaceuticals on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Biostar Pharmaceuticals or generate 0.0% return on investment in Biostar Pharmaceuticals over 90 days. Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter and prescription pharmaceutical produ... More
Biostar Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Biostar Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Biostar Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
Biostar Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biostar Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Biostar Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Biostar Pharmaceuticals historical prices to predict the future Biostar Pharmaceuticals' volatility.Biostar Pharmaceuticals Backtested Returns
We have found three technical indicators for Biostar Pharmaceuticals, which you can use to evaluate the volatility of the firm. The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Biostar Pharmaceuticals are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Biostar Pharmaceuticals has perfect predictability. Overlapping area represents the amount of predictability between Biostar Pharmaceuticals time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Biostar Pharmaceuticals price movement. The serial correlation of 1.0 indicates that 100.0% of current Biostar Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Biostar Pharmaceuticals reported net income of (5.7 Million). This is 101.67% lower than that of the Pharmaceuticals sector and significantly lower than that of the Pharmaceuticals, Biotechnology & Life Sciences industry. The net income for all United States stocks is 101.0% higher than that of the company.
Biostar Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biostar Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Biostar Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Biostar Pharmaceuticals by comparing valuation metrics of similar companies.Biostar Pharmaceuticals is currently under evaluation in net income category among its peers.
Biostar Fundamentals
| Return On Equity | 0.0266 | |||
| Return On Asset | 0.0425 | |||
| Profit Margin | 2.94 % | |||
| Operating Margin | 8.76 % | |||
| Current Valuation | 316.46 K | |||
| Shares Outstanding | 2.64 M | |||
| Number Of Shares Shorted | 170.44 K | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.0001 X | |||
| Revenue | 317.79 K | |||
| Gross Profit | 915.17 K | |||
| EBITDA | (1.7 M) | |||
| Net Income | (5.7 M) | |||
| Cash And Equivalents | 364.97 K | |||
| Cash Per Share | 0.14 X | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 0.19 X | |||
| Book Value Per Share | 13.71 X | |||
| Cash Flow From Operations | 4.91 M | |||
| Short Ratio | 3.00 X | |||
| Earnings Per Share | 0.06 X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 200 | |||
| Beta | -2923.36 | |||
| Market Capitalization | 94 | |||
| Total Asset | 42.5 M | |||
| Retained Earnings | 3.16 M | |||
| Working Capital | 9.07 M | |||
| Current Asset | 16.17 M | |||
| Current Liabilities | 7.1 M | |||
| Net Asset | 42.5 M |
About Biostar Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biostar Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biostar Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biostar Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Biostar Pink Sheet
Biostar Pharmaceuticals financial ratios help investors to determine whether Biostar Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostar with respect to the benefits of owning Biostar Pharmaceuticals security.